Sponsors (2)
The resolution would likely improve detection, awareness, and appropriate treatment of tardive dyskinesia for people on antipsychotics, but without dedicated funding or balanced clinical guidance it risks added costs and workload and could unintentionally discourage necessary antipsychotic use.
People receiving antipsychotic medications: more likely to receive routine screening and earlier diagnosis for tardive dyskinesia (TD), improving symptom management and quality of life.
Clinicians and healthcare systems: receive targeted education about TD and recommendations aligned with FDA‑approved treatments, improving detection rates and appropriate use of available therapies for diagnosed individuals.
People with TD and their care partners: benefit from greater public awareness that can reduce stigma and encourage earlier assessments and treatment-seeking.
Patients with serious mental illness and prescribers: emphasis on antipsychotic‑linked TD could inadvertently discourage appropriate antipsychotic use if not accompanied by balanced guidance, risking undertreatment of severe psychiatric conditions.
Patients (especially low‑income individuals): increased screening may lead to more TD diagnoses and greater demand for specialized treatments, raising out‑of‑pocket costs if coverage gaps exist.
Clinicians and clinic workflows: encouraging additional screening and education without new funding could increase clinician workload and appointment time, straining already limited resources.
Based on analysis of 2 sections of legislative text.
Urges increased attention, education, and routine screening for tardive dyskinesia (TD) linked to antipsychotic medicines, citing rising antipsychotic use and available treatments. It identifies groups at higher risk—older adults, Black individuals, women, people with mood or substance use disorders, intellectual disabilities, CNS injuries, and those with high cumulative antipsychotic exposure—and notes many cases are undiagnosed. Encourages clinicians, patients, and care partners to follow best practices including regular TD screening and greater awareness so that cases are identified and treated promptly; the measure recommends education and awareness efforts but does not create new funding or authorize programs.
Introduced October 30, 2025 by Markwayne Mullin · Last progress October 30, 2025